{"id":"W2259669113","doi":"10.1200/jco.2012.30.18_suppl.lba3500","title":"Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy and safety results of the International GERCOR DREAM phase III trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Bevacizumab; FOLFOX; FOLFIRI; Internal medicine; Erlotinib; Oncology; Regimen; Clinical endpoint; Colorectal cancer; Maintenance therapy; Chemotherapy regimen; Chemotherapy; Randomized controlled trial; Surgery; Irinotecan; Cancer; Oxaliplatin; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008798217,0.0004752786,0.001155577,0.0002131577,0.0001797344,0.0005839744,0.0004920102,0.0005858372,0.001858047],"category_scores_gemma":[0.0006793176,0.0002499412,0.0006301791,0.0003304534,0.0004299474,0.0003677273,0.0002895954,0.001254583,0.0003143567],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000833729,"about_ca_system_score_gemma":0.0009882814,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001595548,"about_ca_topic_score_gemma":0.00562864,"domain_scores_codex":[0.9997674,0.0001235459,0.00001447439,0.00003234891,0.00002144721,0.00004088003],"domain_scores_gemma":[0.9996526,0.00006532726,0.00008792547,0.00001923099,0.00001314295,0.000161772],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8667659,0.01086381,0.007551746,0.000675221,0.001088212,0.00009298365,0.0001133723,0.001293016,0.008677111,0.0001724118,0.002350532,0.1003556],"study_design_scores_gemma":[0.6700515,0.3007683,0.02088987,0.0000905059,0.001048288,0.0002741573,0.00005248841,0.001465179,0.002286197,0.0001932592,0.002859212,0.00002111807],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951297,0.002478953,0.0001947074,0.0002307921,0.00005225144,0.0004982766,0.0004029128,0.00003844301,0.0009739425],"genre_scores_gemma":[0.9952416,0.001510651,0.0005735193,0.0002948193,0.00007629355,0.0004429089,0.0008522104,0.000007566326,0.001000354],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001858047,"threshold_uncertainty_score":0.006215811,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08769956509549208,"score_gpt":0.4415433121029494,"score_spread":0.3538437470074573,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}